{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T08:58:01Z","timestamp":1793177881056,"version":"4.5.0"},"reference-count":21,"publisher":"Japanese Society of Internal Medicine","issue":"14","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2024,7,15]]},"DOI":"10.2169\/internalmedicine.2870-23","type":"journal-article","created":{"date-parts":[[2023,11,19]],"date-time":"2023-11-19T22:12:40Z","timestamp":1700431960000},"page":"1995-1999","source":"Crossref","is-referenced-by-count":6,"title":["BRAF V600E-mutated Colorectal Neuroendocrine Carcinoma Effectively Treated with a Chemotherapy Protocol for BRAF-mutated Metastatic Colorectal Cancer"],"prefix":"10.2169","volume":"63","author":[{"given":"Seira","family":"Owaki","sequence":"first","affiliation":[{"name":"Department of Gastroenterology, Nagoya City University West Medical Center, Japan"},{"name":"Department of Medical Oncology, National Hospital Organization Nagoya Medical Center, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshinori","family":"Mori","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Nagoya City University West Medical Center, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shunsuke","family":"Nakai","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Nagoya City University West Medical Center, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideki","family":"Maeda","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Nagoya City University West Medical Center, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitsuki","family":"Imazu","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Nagoya City University West Medical Center, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusaku","family":"Tomita","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Nagoya City University West Medical Center, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroki","family":"Kanaiwa","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Nagoya City University West Medical Center, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayana","family":"Yamaguchi","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Nagoya City University West Medical Center, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mika","family":"Kitagawa","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Nagoya City University West Medical Center, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsuyuki","family":"Hirano","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Nagoya City University West Medical Center, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshihide","family":"Kimura","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Nagoya City University West Medical Center, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenji","family":"Tsuchida","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Nagoya City University West Medical Center, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiromi","family":"Kataoka","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Metabolism, Nagoya City University Graduate School of Medical Sciences, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Bernick PE, Klimstra DS, Shia J, et al. Neuroendocrine carcinomas of the colon and rectum. Dis Colon Rectum 47: 163-169, 2004.","DOI":"10.1007\/s10350-003-0038-1"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Conte B, George B, Overman M, et al. High-grade neuroendocrine colorectal carcinomas: a retrospective study of 100 patients. Clin Colorectal Cancer 15: e1-e7, 2016.","DOI":"10.1016\/j.clcc.2015.12.007"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Shen C, Tannenbaum D, Horn R, et al. Overall survival in phase 3 clinical trials and the surveillance, epidemiology, and end results database in patients with metastatic colorectal cancer, 1986-2016: a systematic review. JAMA Netw Open 5: e2213588, 2022.","DOI":"10.1001\/jamanetworkopen.2022.13588"},{"key":"4","unstructured":"4. Morizane C, Machida N, Honma Y, et al. Effectiveness of etoposide and cisplatin vs irinotecan and cisplatin therapy for patients with advanced neuroendocrine carcinoma of the digestive system: the TOPIC-NEC phase 3 randomized clinical trial. JAMA Oncol 8: 1447-1455, 2022."},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Burkart J, Owen D, Shah MH, et al. Targeting BRAF mutations in high-grade neuroendocrine carcinoma of the colon. J Natl Compr Canc Netw 16: 1035-1040, 2018.","DOI":"10.6004\/jnccn.2018.7043"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Dizdar L, Werner TA, Drusenheimer JC, et al. BRAF<sup>V600E<\/sup> mutation: a promising target in colorectal neuroendocrine carcinoma. Int J Cancer 144: 1379-1390, 2019.","DOI":"10.1002\/ijc.31828"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Cremolini C, Antoniotti C, Stein A, et al. Individual patient data meta-analysis of FOLFOXIRI plus bevacizumab versus doublets plus bevacizumab as initial therapy of unresectable metastatic colorectal cancer. J Clin Oncol JCO2001225, 2020.","DOI":"10.1200\/JCO.20.01225"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Kopetz S, Grothey A, Yaeger R, et al. Encorafenib, binimetinib, and cetuximab in BRAF V600E-mutated colorectal cancer. N Engl J Med 381: 1632-1643, 2019.","DOI":"10.1056\/NEJMoa1908075"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Fazio N, Spada F, Giovannini M. Chemotherapy in gastroenteropancreatic (GEP) neuroendocrine carcinomas (NEC): a critical view. Cancer Treat Rev 39: 270-274, 2013.","DOI":"10.1016\/j.ctrv.2012.06.009"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Garcia-Carbonero R, Anton-Pascual B, Modrego A, et al. Advances in the treatment of gastroenteropancreatic neuroendocrine carcinomas: are we moving forward? Endocr Rev 44: 724-736, 2023.","DOI":"10.1210\/endrev\/bnad006"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Ooki A, Osumi H, Fukuda K, Yamaguchi K. Potent molecular-targeted therapies for gastro-entero-pancreatic neuroendocrine carcinoma. Cancer Metastasis Rev 42: 1021-1054, 2023.","DOI":"10.1007\/s10555-023-10121-2"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Yamaguchi T, Machida N, Morizane C, et al. Multicenter retrospective analysis of systemic chemotherapy for advanced neuroendocrine carcinoma of the digestive system. Cancer Sci 105: 1176-1181, 2014.","DOI":"10.1111\/cas.12473"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Mollazadegan K, Welin S, Crona J. Systemic treatment of gastroenteropancreatic neuroendocrine carcinoma. Curr Treat Options Oncol 22: 68, 2021.","DOI":"10.1007\/s11864-021-00866-9"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Corcoran RB, Atreya CE, Falchook GS, et al. Combined BRAF and MEK inhibition with dabrafenib and trametinib in BRAF V600-mutant colorectal cancer. J Clin Oncol 33: 4023-4031, 2015.","DOI":"10.1200\/JCO.2015.63.2471"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Klempner SJ, Gershenhorn B, Tran P, et al. <i>BRAF<\/i><sup>V600E<\/sup> mutations in high-grade colorectal neuroendocrine tumors may predict responsiveness to BRAF-MEK combination therapy. Cancer Discov 6: 594-600, 2016.","DOI":"10.1158\/2159-8290.CD-15-1192"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Nakano M, Shimada Y, Matsumoto Y, et al. Efficacy of BRAF inhibitor and anti-EGFR antibody in colorectal neuroendocrine carcinoma. Clin J Gastroenterol 15: 413-418, 2022.","DOI":"10.1007\/s12328-022-01599-4"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Nagtegaal ID, Odze RD, Klimstra D, et al. The 2019 WHO classification of tumors of the digestive system. Histopathology 76: 182-188, 2020.","DOI":"10.1111\/his.13975"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Chen L, Liu M, Zhang Y, Guo Y, Chen MH, Chen J. Genetic characteristics of colorectal neuroendocrine carcinoma: more similar to colorectal adenocarcinoma. Clin Colorectal Cancer 20: 177-185 e13, 2021.","DOI":"10.1016\/j.clcc.2020.09.001"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Collot T, Fumet JD, Klopfenstein Q, Vincent J, Bengrine L, Ghiringhelli F. Bevacizumab-based chemotherapy for poorly differentiated neuroendocrine tumors. Anticancer Res 38: 5963-5968, 2018.","DOI":"10.21873\/anticanres.12943"},{"key":"20","unstructured":"20. National Comprehensive Cancer Network. Neuroendocrine and Adrenal Tumors (Version 1. 2023). NCCN clinical practice guidelines in oncology 2023."},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Hadoux J, Afchain P, Walter T, et al. FOLFIRINEC: a randomized phase II trial of mFOLFIRINOX vs platinum-etoposide for metastatic neuroendocrine carcinoma of gastroenteropancreatic or unknown origin. Dig Liver Dis 53: 824-829, 2021.","DOI":"10.1016\/j.dld.2021.04.016"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/63\/14\/63_2870-23\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,20]],"date-time":"2024-07-20T03:30:20Z","timestamp":1721446220000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/63\/14\/63_2870-23\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,15]]},"references-count":21,"journal-issue":{"issue":"14","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.2870-23","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,15]]},"article-number":"2870-23"}}